Biotech was in such bad shape eight months ago, Steve Gillis said it was like a patient being hit by waves of chemotherapy. Companies were struggling to survive the longest run of investor fear in two decades.
Biotech was in such bad shape eight months ago, Steve Gillis said it was like a patient being hit by waves of chemotherapy. Companies were struggling to survive the longest run of investor fear in two decades.